Literature DB >> 28041941

A simple flow-cytometry method to evaluate peripheral blood contamination of bone marrow aspirates.

José Antonio Delgado1, Francisco Guillén-Grima2, Cristina Moreno1, Carlos Panizo3, Carmen Pérez-Robles1, Juan José Mata1, Laura Moreno1, Paula Arana1, Silvia Chocarro1, Juana Merino4.   

Abstract

Bone marrow (BM) aspirates used for flow-cytometry (FCM) studies are usually obtained from a second aspiration, as the primary aspirate is used for morphological assessment. For this reason, the FCM samples unavoidably contain some blood; although, good-quality samples contain only a small amount. It is of utmost importance to assess the quality of samples prior to FCM analysis; yet, contamination with peripheral blood (PB) is not evaluated in most laboratories, possibly because the methods available are either qualitative or too complex for daily practice. Here, we propose a simple FCM method to quantitatively evaluate PB contamination in BM aspirates, by analyzing the percentage of plasma cells and CD34+ cells - two cell populations nearly absent from PB - and CD10+ granulocytes, which comprise the majority of the PB granulocyte population. We analyzed these three populations in 122 BM aspirates from subjects without hematological disease, and identified samples with PB contamination by performing a hierarchical cluster analysis. A discriminant analysis yielded a function, which we named the PB contamination index (PBCI). This index value gives a quantitative indication about the degree of hemodilution of a given sample. A threshold was identified that discriminates low-quality samples. The method and the threshold proved to be useful in BM aspirates infiltrated with malignant cells, with the exception of cases where hematological disease altered two of the three parameters included in the index. We have easily implemented the PBCI calculation in our daily routine, and find it very helpful for an accurate interpretation of FCM results in a large proportion of BM specimens. Limitations of the technique are discussed.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  BM aspirates; Flow cytometry; PB contamination; Quality; Samples

Mesh:

Substances:

Year:  2016        PMID: 28041941     DOI: 10.1016/j.jim.2016.12.006

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  10 in total

1.  Bone Marrow Stromal Cell Regeneration Profile in Treated B-Cell Precursor Acute Lymphoblastic Leukemia Patients: Association with MRD Status and Patient Outcome.

Authors:  Elen Oliveira; Elaine S Costa; Juana Ciudad; Giuseppe Gaipa; Łukasz Sedek; Susana Barrena; Tomasz Szczepanski; Chiara Buracchi; Daniela Silvestri; Patrícia F R Siqueira; Fabiana V Mello; Rafael C Torres; Leonardo M R Oliveira; Isabelle V C Fay-Neves; Edwin Sonneveld; Vincent H J van der Velden; Esther Mejstrikova; Josep-Maria Ribera; Valentino Conter; Martin Schrappe; Jacques J M van Dongen; Marcelo G P Land; Alberto Orfao
Journal:  Cancers (Basel)       Date:  2022-06-23       Impact factor: 6.575

2.  Plasmodium in the bone marrow: case series from a hospital in Pakistan, 2007-2015.

Authors:  Muhammad Shariq Shaikh; Basim Ali; Mahin Janjua; Ayesha Akbar; Syed Arish Haider; Bushra Moiz; Ahmed Raheem; John Kevin Baird; Mohammad Asim Beg
Journal:  Malar J       Date:  2021-06-08       Impact factor: 2.979

3.  Baseline identification of clonal V(D)J sequences for DNA-based minimal residual disease detection in multiple myeloma.

Authors:  Even H Rustad; Malin Hultcrantz; Venkata D Yellapantula; Theresia Akhlaghi; Caleb Ho; Maria E Arcila; Mikhail Roshal; Akshar Patel; Denise Chen; Sean M Devlin; Austin Jacobsen; Ying Huang; Jeffrey E Miller; Elli Papaemmanuil; Ola Landgren
Journal:  PLoS One       Date:  2019-03-22       Impact factor: 3.240

4.  Evaluation of Sample Quality As Preanalytical Error in Flow Cytometry Analysis in Childhood Acute Lymphoblastic Leukemia.

Authors:  Eszter Szánthó; Bettina Kárai; Gergely Ivády; Sándor Baráth; Marianna Száraz-Széles; János Kappelmayer; Zsuzsanna Hevessy
Journal:  EJIFCC       Date:  2019-11-25

5.  Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working Party.

Authors:  Jesse M Tettero; Sylvie Freeman; Veit Buecklein; Adriano Venditti; Luca Maurillo; Wolfgang Kern; Roland B Walter; Brent L Wood; Christophe Roumier; Jan Philippé; Barbara Denys; Jeffrey L Jorgensen; Marie C Bene; Francis Lacombe; Adriana Plesa; Monica L Guzman; Agnieszka Wierzbowska; Anna Czyz; Lok Lam Ngai; Adrian Schwarzer; Costa Bachas; Jacqueline Cloos; Marion Subklewe; Michaela Fuering-Buske; Francesco Buccisano
Journal:  Hemasphere       Date:  2021-12-22

Review 6.  Drug resistance and minimal residual disease in multiple myeloma.

Authors:  Alessandro Gozzetti; Sara Ciofini; Anna Sicuranza; Paola Pacelli; Donatella Raspadori; Emanuele Cencini; Dania Tocci; Monica Bocchia
Journal:  Cancer Drug Resist       Date:  2022-02-16

7.  Flow Cytometric Analysis of Bone Marrow Particle Cells for Measuring Minimal Residual Disease in Multiple Myeloma.

Authors:  Duanfeng Jiang; Yanan Zhang; Shiming Tan; Jing Liu; Xin Li; Congming Zhang
Journal:  Cancers (Basel)       Date:  2022-10-08       Impact factor: 6.575

Review 8.  Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party.

Authors:  Gerrit J Schuurhuis; Michael Heuser; Sylvie Freeman; Marie-Christine Béné; Francesco Buccisano; Jacqueline Cloos; David Grimwade; Torsten Haferlach; Robert K Hills; Christopher S Hourigan; Jeffrey L Jorgensen; Wolfgang Kern; Francis Lacombe; Luca Maurillo; Claude Preudhomme; Bert A van der Reijden; Christian Thiede; Adriano Venditti; Paresh Vyas; Brent L Wood; Roland B Walter; Konstanze Döhner; Gail J Roboz; Gert J Ossenkoppele
Journal:  Blood       Date:  2018-01-12       Impact factor: 25.476

Review 9.  Minimal Residual Disease in Multiple Myeloma: State of the Art and Applications in Clinical Practice.

Authors:  Alessandro Gozzetti; Donatella Raspadori; Francesca Bacchiarri; Anna Sicuranza; Paola Pacelli; Ilaria Ferrigno; Dania Tocci; Monica Bocchia
Journal:  J Pers Med       Date:  2020-09-10

10.  Daratumumab in AL Amyloidosis: A Real-Life Experience of the "RTM" (Regional Tuscan Myeloma Network).

Authors:  Vincenzo Sammartano; Elisabetta Antonioli; Gabriele Buda; Sara Ciofini; Veronica Candi; Ludovica Pengue; Maria Livia Del Giudice; Irene Attucci; Francesca Bacchiarri; Ubaldo Occhini; Maria Teresa Pirrotta; Federico Perfetto; Monica Bocchia; Alessandro Gozzetti
Journal:  J Pers Med       Date:  2022-03-17
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.